Dear Shareholders and Friends of Histogen,

As we enter the third quarter of 2019, I am pleased to share our progress from recent months as well as look ahead to the significant milestones that will help shape the future direction of the Company.

I would first like to highlight the development of SkinMedica’s TNS A+ Pro, which is set to launch later this year. Histogen has worked closely with Allergan throughout product development and clinical testing and we are pleased to continue our partnership with Allergan to incorporate our multipotent cell conditioned media (CCM) into their full line of skin care products. This new dual serum was evaluated through a comprehensive clinical study and yielded unprecedented results including rapid, significant reduction in fine lines and wrinkles and improvement in skin texture. The results of that work have been submitted for publication and are expected to be announced later this summer.

One of our key corporate objectives for this year is to build upon the success we have seen in the dermatology space with our partners Allergan and HydraFacial with a focus on further validating our CCM technology and securing non-dilutive capital to fuel our growth. We are currently in the process of identifying a luxury skin care partner to bring Histogen’s CCM into the retail sector. This has been a dynamic process over the past few months with multiple parties, including the most prominent worldwide beauty companies, actively engaged in a process which we expect will lead to a transaction later this year.

On the clinical front, the data analysis from the Phase 1 clinical trial of HSC660 in female hair loss has recently been completed. Excellent safety and tolerability of the product was seen, meeting all primary trial endpoints. We will continue to evaluate the HSC development pathway in both men and women with the goal of moving it forward in late-stage clinical trials early next year.

Finally, we are completing our comprehensive portfolio assessment which will identify key product opportunities for Histogen’s human extracellular matrix (hECM) technology in the orthopedic and aesthetics markets. We see tremendous opportunity to address unmet need with hECM in these therapeutic areas and now that we have re-gained control of these assets, our goal is to bring one or more into clinical development as early as Q4 2019.

I continue to be incredibly proud of the progress we have made this year and I look forward to sharing further news and updates with you throughout the year. Thank you for your continued support!

Warm Regards.


Richard W. Pascoe
Chairman & Chief Executive Officer

Dear Shareholders and Friends of Histogen,

Histogen was founded in 2007 with a vision to develop innovative products that redefine regenerative medicine. Although the company has experienced its share of triumphs and challenges since its founding, the one constant throughout the company’s history has been its commitment to developing high value therapeutic and aesthetic products which harness the healing powers of our body’s own stem cells. It was this commitment to innovation that attracted me to join the company as Chairman and CEO in late January.

I have spent more than 25 years leading organizations in transition, most recently serving as CEO of Apricus Biosciences, where we obtained European regulatory approval for our lead asset and subsequently completed a successful merger with Seelos Therapeutics. Over the course of my career, I have been responsible for raising over $250 million in equity capital, leading an IPO process as Lead Director for a specialty pharmaceutical company, and leading multiple business development transactions valued at over $2 billion. A link to my full bio is here. My intent is to leverage that experience as I guide the company through its next stages of clinical, corporate, and financial growth with the goal of maximizing shareholder value.

Looking forward, we have several important milestones ahead of us to include reporting safety and tolerability data from our Phase 1 clinical trial of HSC660 in female diffuse hair loss, obtaining regulatory guidance for our HSC hair loss program, completing our outstanding financial audits and completing a full review and assessment of our pipeline opportunities. In addition, we are pursuing potential partnerships in the retail skin care segment which we believe will further validate our technology and bring precious non-dilutive capital into the company to fuel our growth.

Finally, I am proud to announce two exciting updates on the corporate development front. First, we recently expanded our relationship with our aesthetics skincare partner Allergan through an amended license to include certain new exclusive and non-exclusive channels. This transaction is expected to fund the company through the end of 2019 and accelerate the timing of certain commercial milestone payments with the expected launch of two new products containing our multipotent cell conditioned media within the SkinMedica TNS skin care line, including a dual serum that showed unprecedented anti-aging benefits in Allergan’s clinical study. Second, we recently terminated our partnership with PUR Biologics, resulting in Histogen regaining full control of our ECM products in several important areas of therapeutic interest such as orthopedics and wound healing. Following a strategic review of these opportunities, we plan on selecting and advancing one or more into the clinic.

In closing, I am incredibly proud of the progress we have made this year and I look forward to sharing further news and updates with you throughout the year. Thank you for your continued support!

Warm Regards.


Richard W. Pascoe
Chairman & Chief Executive Officer